Appendix #1



NuGrowthRX™ Prescription Medication Studies

A. Androgenetic Alopecia Studies

 

  1. Asfour L, Cranwell W, Sinclair R. Male Androgenetic Alopecia. [Updated 2023 Jan 25]. In: Feingold KR, Anawalt B, Blackman MR, et al., editors.

Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278957/

  1. Ring C, Heitmiller K, Correia E, Gabriel Z, Saedi N.

Nutraceuticals for Androgenetic Alopecia. J Clin Aesthet Dermatol. 2022 Mar;15(3):26-29. PMID: 35342503; PMCID: PMC8944288.

  1. Völker JM, Koch N, Becker M, Klenk

Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review. Skin Pharmacol Physiol. 2020;33(3):93-109. doi: 10.1159/000508228. Epub 2020 Jun 29. PMID: 32599587.

  1. Fabbrocini G, Cantelli M, Masarà A, Annunziata MC, Marasca C, Cacciapuoti S

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Int J Womens Dermatol. 2018 Jun 19;4(4):203-211. doi: 10.1016/j.ijwd.2018.05.001. PMID: 30627618; PMCID: PMC6322157.

  1. Trüeb RM, Rezende HD, Dias MFRG. A Comment on the Science of Hair Aging. Int J Trichology.

2018 Nov-Dec;10(6):245-254. doi: 10.4103/ijt.ijt_56_18. PMID: 30783331; PMCID: PMC6369639.

  1. Levy LL, Emer Female pattern alopecia: current perspectives.

Int J Womens Health. 2013 Aug 29;5:541-56. doi: 10.2147/IJWH.S49337. PMID: 24039457;PMCID: PMC3769411.

  1. Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G.

Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012 Mar 21;4(126):126ra34. doi: 10.1126/scitranslmed.3003122. PMID: 22440736; PMCID: PMC3319975. 

  1. Khandpur, , Suman, M. and Reddy, B.S. (2002),

Comparative Efficacy of Various Treatment Regimens for Androgenetic Alopecia in Men. The Journal of Dermatology, 29: 489-498. https://doi.org/10.1111/j.1346-8138.2002.tb00314.x

  1. SHAW, C. (1996), Antiandrogen Therapy in Dermatology.

International Journal of Dermatology, 35: 770-778. https://doi.org/10.1111/j.1365-4362.1996.tb02970.x

  1. Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023 Jun;83(8):701-715. doi: 10.1007/s40265-023-01880-x. Epub 2023 May 11. PMID: 37166619; PMCID: PMC10173235.

 

B. Hair Loss Scale Studies:

  1. Won-Soo Lee, MD, PhD,a Byung In Ro, MD, PhD, et al A new classification of pattern hair loss  that is universal for men and women:

Basic and specific (BASP) classification. J Am Acad Dermatol 2007;57:37-46.

  1. Guarrera M, Cardo P, Arrigo P, Rebora A (2009). “Reliability of hamilton-norwood classification“. Int J Trichology. 1 (2): 120–2. doi:4103/0974-7753.58554. PMC 2938573. PMID 20927233.
  2. Gupta, M; Mysore, V (2016). “Classifications of Patterned Hair Loss: A Review”. Journal of Cutaneous and Aesthetic Surgery. 9(1): 3–12. doi:4103/0974-2077.178536. PMC 4812885. PMID 27081243.
  3. Ludwig Scale for Female Hair Loss Dermatology (4 ed.). Elsevier. 2018. pp. 2637–2648.
  1. Alvi Armani Hair loss scale https://www.alviarmani.com/hair-loss-help/hair-loss-scale/
  2. Anish Biswas and Mohd Almas Khan A Complete Examination of The Intricate Factors Involved in Baldness Department of Pharmaceutical Science, Lovely Professional University, Jalandhar144401, India Received: 12 Oct 2021 / Accepted: 6 Nov 2021/ Published online: 01 Jan 2022 *
  1. Agarwal S, Godse K, Mahajan A, Patil S, Nadkarni N. Application of the basic and specific classification on patterned hair loss in Indians.

Int J Trichology. 2013 Jul;5(3):126-31. doi: 10.4103/0974-7753.125606. PMID: 24574690; PMCID: PMC3927169.

  1. Bouhanna P. Multifactorial classification of male and female androgenetic alopecia.

Dermatol Surg. 2000 Jun;26(6):555-61. doi: 10.1046/j.1524-4725.2000.00009.x. PMID: 10848937

 

 

C. Minoxidil Studies:

  1. Bergfeld W., Oral minoxidil offers Strong, Results Against Alopecia; Cleveland Clinic, Dermatology and Plastic Surgery, October 13, 2022
  2. Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatol. 2022;158(3):266–274. doi:10.1001/jamadermatol.2021.5743
  1. Dermatologists Embrace Low-Dose Oral Minoxidil as Hair Loss Adjunctive Therapy– Medscape – Oct 12, 2022.
  2. Oral Minoxidil for Hair Loss: What to Know About Off-Label Use of the Drug. Korin Miller Health magazine September 2022
  3. Ramírez-Marín HA, Tosti A. Role of Oral Minoxidil in Patterned Hair Loss. Indian Dermatol Online J. 2022 Oct 12;13(6):729-733. doi: 10.4103/idoj.idoj_246_22. PMID: 36386734; PMCID: PMC9650732.

 

  1. Vañó-Galván S, et.al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Am. Acad. Dermatol. 2021;84(6):1644–1651.
  1. Sadegh Vahabi-Amlashi, Pouran Layegh et al. A randomized clinical trial on therapeutic effects of 0.25 mg oral minoxidil tablets on treatment of female pattern hair loss.Dermatology Therapy Volume 34,Issue 6 November/December 2021.
  1. Bokhari, L.N. Jones, R.D. Sinclair Sublingual minoxidil for the treatment of male and female pattern hair loss: a randomized, double-blind, placebo-controlled, phase 1B clinical trial Journal of the European Academy of Dermatology and Venereology: JEADV Published in Dermatology Journal Scan / Research · September 19, 2021 First published: 22 August 2021
  1. Villani, G. Fabbrocini,  J. Ocampo-Candiani,  A. Ruggiero,  S.S. Ocampo-Garza Review of oral minoxidil as treatment of hair disorders: in search of the perfect dose

Journal of the European Academy of Dermatology & Venereology; Pages: 1485-1492; First Published: 03 March 2021 Volume 35, Issue

  1. Rodrigues-Barata R, Moreno-Arrones OM, Saceda-Corralo D, Jiménez-Cauhé J, Ortega-Quijano D, Fernández-Nieto D, Jaén-Olasolo P, Vaño-Galvan S.

Low-Dose Oral Minoxidil for Female Pattern Hair Loss: A Unicenter Descriptive Study of 148 Women. Skin Appendage Disord. 2020 Jun;6(3):175-176. doi: 10.1159/000505820. Epub 2020 Feb 21. PMID: 32656239; PMCID: PMC7325226.

  1. Sinclair, L. Trindade de Carvalho, F. Ferial Ismail, N. Meah Treatment of male and female pattern hair loss with sublingual minoxidil: a retrospective case-series of 64 patientsJournal of the European Academy of Dermatology and Venereology Volume 34, Issue 12 First published: 09 May 2020
  1. do Nascimento IJB, Harries M, Rocha VB, Thompson JY, Wong CH, Varkaneh HK, Guimarães NS, Rocha Arantes AJ, Marcolino MS. Effect of Oral Minoxidil for Alopecia: Systematic Review. Int. J. Trichology. 2020;12(4):147–155.
  1. Panchaprateep R, Lueangarun S. Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment. Dermatol. Ther. 2020;10(6):1345–1357. [PMC free article] [PubMed]
  1. Beach R, McDonald K, Barrett B. Tolerated, Effective, Successful: Low Dose Oral Minoxidil for Treating Alopecia, A 3-Year North American Retrospective Case Series. J Am Acad Dermatol 2020 doi: 10.1016/j.jaad.2020.10.032.
  1. Therianou A, Vincenzi C, Tosti A, How safe is prescribing oral minoxidil in patients allergic to topical minoxidil? Journal of the American Academy of Dermatology (2020), doi:https://doi.org/10.1016/j.jaad.2020.04.027
  1. Randolph M, Tosti A. Oral minoxidil treatment for hair loss: A review of efficacy and safety.J Am Acad Dermatol. 2021 Mar;84(3):737-746. doi: 10.1016/j.jaad.2020.06.1009. Epub 2020 Jul 2. PMID: 32622136.
  1. Maria Vastarella 1, Mariateresa Cantelli 1, Angela Patrì 1, Maria Carmela Annunziata 1, Paola Nappa1, Gabriella Fabbrocini 1 Efficacy and safety of oral minoxidil in female androgenetic alopecia Dermatol Ther 2020 Nov;33(6):e14234. doi: 10.1111/dth.14234. Epub 2020 Sep 14.
  1. Paulo Müller Ramos, Rodney D. Sinclair, Michal Kasprzak, Hélio Amante Miot MD,PhD

Minoxidil 1 mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: A randomized clinical trial

 Journal of the American Academy of Dermatology, 2020; Volume 82, Issue 1, 252 – 253

  1. Jha, Abhijeet Kumar et al. Efficacy and safety of very-low-dose oral minoxidil 1.25 mg in male androgenetic alopecia Journal of the American Academy of Dermatology, Volume 83, Issue 5, 1491 – 1493 May 2020, https://doi.org/10.1016/j.jaad.2020.05.129
  1. Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Moreno-Arrones OM, Ortega-Quijano D, Fernandez-Nieto D, Jaen-Olasolo P, Vaño-Galvan S. Safety of low-dose oral minoxidil treatment for hair loss. A systematic review and pooled-analysis of individual patient data.Dermatol Ther. 2020 Aug 5:e14106. doi: 10.1111/dth.14106. Epub ahead of print. PMID: 32757405.
  1. Jimenez-Cauhe J, Saceda-Corralo D, Rodrigues-Barata R, Hermosa-Gelbard A, Moreno-Arrones OM,Fernandez-Nieto D, Vaño- Galvan Effectivenessand safety of low-dose oral minoxidil in maleandrogenetic alopecia. J Am Acad Dermatol. 2019 Aug;81(2):648-649. doi: 10.1016/j.jaad.2019.04.054. Epub 2019 May 2. PMID: 31054970.
  1. Pindado-Ortega C, Saceda-Corralo D, Vañó-Galván Oral Minoxidil for Female Pattern Hair Loss and Other Alopecias; AKA Minoxidil oral para el tratamiento de la alopecia androgénica femenina y otras alopecias FR –Actas Dermosifiliogr. 2019;110:861–862.
  1. Lyakhovitsky A, Segal O, Maly A, Zlotogorski A, Barzilai A. Permanent chemotherapy-induced alopecia after hematopoietic stem cell transplantation treated with low-dose oral minoxidil. JAAD Case Rep. 2022 Feb 17;22:64-67. doi: 10.1016/j.jdcr.2022.01.035. PMID: 35321258; PMCID: PMC8935347.
  1. Pirmez R, Salas-Callo C-I. Very-low-dose oral minoxidil in male androgenetic alopecia: A study with quantitative trichoscopic documentation. J Am Acad Dermatol. 2020;82(1):e21-e22. doi:10.1016/j.

jaad.2019.08.084

  1. Ramos PM, Sinclair RD, Kasprzak M, Miot HA. Minoxidil 1mg oral versus minoxidil 5% topical solution for the treatment of female-pattern hair loss: a randomized clinical trial. J Am Acad Dermatol. 2020;82(1):252–3.  
  1. Sharma AN, Michelle L, Juhasz M, Muller Ramos P, Atanaskova Mesinkovska N. Low-dose oral minoxidil as treatment for non-scarring alopecia: a systematic review. Int J Dermatol. 2020 Aug;59(8):1013-1019. doi: 10.1111/ijd.14933. Epub 2020 Jun 9. PMID: 32516434. NEW

 

D. Combined Minoxidil and Spironolactone Studies:

  1. Brianna Olamiju, Brittany Craiglow,

Combination oral minoxidil and spironolactone for the treatment of androgeneticalopecia in adolescent girls,

Journal of the American Academy of Dermatology, Volume 84, Issue 6, 2021, Pages 1689-1691,

  1. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.Australas J Dermatol. 2007 Feb;48(1):43-5. doi: 10.1111/j.1440-0960.2007.00332.x. PMID: 17222303.

 

  1. Sinclair RD. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.

Int J Dermatol. 2018 Jan;57(1):104-109. doi: 10.1111/ijd.13838. Epub 2017 Dec 12. PMID: 29231239.

 

 

 

E. Spironolactone Studies:

  1. Burns LJ, De Souza B, Flynn E, Hagigeorges D, Senna MM. Spironolactone for treatment of female pattern hair loss. J Am Acad Dermatol. 2020 Jul;83(1):276-278. doi: 10.1016/j.jaad.2020.03.087. Epub 2020 Apr 5. PMID: 32259535.
  2. Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Clin Cosmet Investig Dermatol. 2023 Mar 9;16:603-612. doi: 10.2147/CCID.S398950. PMID: 36923692; PMCID: PMC10010138.
  3. Adamopoulos DA, Karamertzanis M, Nicopoulou S, Gregoriou A. Beneficial effect of spironolactone on androgenic alopecia. Clin Endocrinol (Oxf). 1997 Dec;47(6):759-60. doi: 10.1046/j.1365-2265.1997.3761162.x. PMID: 9497885.
  4. Corvol P, Michaud A, Menard J, Freifeld M, Mahoudeau

Antiandrogenic effect of spironolactone: mechanism of action. Endocrinology. 1975 Jul;97(1):52-8. doi: 10.1210/endo-97-1-52. PMID: 166833.

  1. Fabbrocini, M. Cantelli, A. Masarà, M.C. Annunziata, C. Marasca, S. Cacciapuoti, Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review, International Journal of Women’s Dermatology, Volume 4, Issue 4,2018,Pages 203-211,ISSN 2352-6475 https://doi.org/10.1016/j.ijwd.2018.05.001. NEW
  1. Sinclair and others, Treatment of female pattern hair loss with oral antiandrogens, British Journal of Dermatology, Volume 152, Issue 3, 1 March 2005, Pages 466–473, https://doi.org/10.1111/j.1365-2133.2005.06218.x NEW
  1. Thai KE, Sinclair RD. Spironolactone-induced hepatitis.Australas J Dermatol. 2001;42(3):180–182. 
  1. Hughes BR, Cunliffe WJ. Tolerance of spironolactone. Br J Dermatol. 1988;118(5):687–691.
  1. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28(3):611–8.
  1. Yazdabadi A, Green J, Sinclair R. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. Australas J Dermatol. 2009;50(2):113–4.

 

F. Finasteride Studies:

  1. B M Piraccini 1, U Blume-Peytavi 2, F Scarci 3, J M Jansat 3, M Falqués 3, R Otero 3, M L Tamarit 3, J Galván 4, V Tebbs 5, E Massana 3, Topical Finasteride Study Group

Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25.

  1. Wimolsiri Iamsumang,1 Kanchana Leerunyakul,1 and Poonkiat Suchonwanit1

Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss:Evidence to Date Drug Des Devel Ther. 2020; 14: 951–959.Published online 2020 Mar 2. doi: 10.2147/DDDT.S240615

  1. Rui Oliveira-Soares, Marisa C André, and Miguel Peres-Correia

Adverse Effects with Finasteride 5 mg/day for Patterned Hair Loss in PremenopausalWomen

Int J Trichology. 2018 Jan-Feb; 10(1): 48–50. doi: 10.4103/ijt.ijt_73_15

  1. Yong-Yon Won,Bark-Lynn Lew,Woo-Young Sim

Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss First published: 20 February 2018 Dermatologic Therapy Volume31, Issue2 March/April 2018

  1. Hirshburg, Jason MD, PhD, Petra A. Kelsey, BS,b Chelsea A. Therrien, BS,b Carlo Gavino, MD,a and Jason S. Reichenberg, MD Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review JClin Aesthet Dermatol. 2016 Jul; 9(7): 56–62.Published online 2016 Jul 1.
  1. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot

The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol 2014;80:521-525

  1. Fertig, R. M, Gamret, A. C, Darwin, , & Gaudi, S. (2017).

Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatology Online Journal, 23(11).

  1. Van Neste, , Fuh, V., Sanchez-Pedreno, P., Lopez-Bran, E., Wolff, H., Whiting, D., Roberts, J., Kopera,D., Stene, J.-J., Calvieri, S., Tosti, A., Prens, E., Guarrera, M., Kanojia, P., He, W. and Kaufman, K. (2000), Finasteride increases anagen hair in menwith androgenetic alopecia. British Journal ofDermatology, 143: 804- 810. https://doi.org/10.1046/j.1365-2133.2000.03780.x
  1. Matilde Iorizzo, MD; Colombina Vincenzi, MD; Stylianos Voudouris, MD; et alBianca Maria Piraccini, MD, PhD; Antonella Tosti, MDFinasteride Treatment of Female Pattern Hair Loss Arch Dermatol. 2006;142(3):298-302. doi:10.1001/archderm.142.3.298
  1. Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldsteicher J. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1999;41(4):550–554.
  1. Kid Wan Shum, Derek R. Cullen, Andrew G. Messenger Hair loss in women with hyperandrogenism: Four cases responding to finasteride, Journal of the American Academy of Dermatology, Volume 47, Issue 5, 2002,Pages 733-739,
  1. Gubelin Harcha W, Barboza Martínez J, Tsai TF, Katsuoka K, Kawashima M, Tsuboi R, Barnes A, Ferron-Brady G, Chetty D. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia. J Am Acad Dermatol. 2014 Mar;70(3):489-498.e3. doi: 10.1016/j.jaad.2013.10.049. Epub 2014 Jan 9. PMID: 24411083.
  1. Mysore V, Shashikumar B M. Guidelines on the use of finasteride in androgenetic alopecia. Indian J Dermatol Venereol Leprol 2016;82:128-134
  1. H. Price, J.L. Roberts, M. Hordinsky, E.A. Olsen, R. Savin, W. Bergfeld, et al. Lack of efficacy of finasteride in post-menopausal women with androgenetic alopecia. J Am Acad Dermatol, 43 (2000), pp. 768-776

 

  1. E. Thai, R.D. Sinclair Finasteride for female androgenetic alopecia Br J Dermatol, 147 (2002), pp. 812-813

 

  1. Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ. Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol. 1998 Oct;39(4 Pt 1):578-89. doi: 10.1016/s0190-9622(98)70007-6. PMID: 9777765.

 

  1. Nobari NN, Roohaninasab M, Sadeghzadeh-Bazargan A, et al. A systematic review of clinical trials using single or combination therapy of oral or topical finasteride for women in reproductive age and postmenopausal women with hormonal and nonhormonal androgenetic alopecia [published online as ahead of print on March 10, 2023]. Adv Clin Exp Med. 2023. doi:10.17219/acem/157990

 

  1. Pallotti F, Senofonte G, Pelloni M, Cargnelutti F, Carlini T, Radicioni AF, Rossi A, Lenzi A, Paoli D, Lombardo F. Androgenetic alopecia: effects of oral finasteride on hormone profile, reproduction and sexual function. 2020 Jun;68(3):688-694. doi: 10.1007/s12020-020-02219-2. Epub 2020 Feb 12. PMID: 32052367.

 

 

G. Dutasteride Studies:

 

  1. Zhongbao Zhou,1,2,* Shiqiang Song,3,* Zhenli Gao,2 Jitao Wu,2 Jiajia Ma,2 and Yuanshan Cui2 The efficacy and safety of dutasteride compared with finasteride in treating men withandrogenetic alopecia: a systematic review and meta-analysis Clin Interv Aging. 2019; 14: 399–406 Published online 2019 Feb
  2. doi: 10.2147/CIA.S192435
  1. Arif, Tasleem; Dorjay, Konchok; Adil, Mohammad; Sami, Marwa Dutasteride in AndrogeneticAlopecia: An Update

Current Clinical Pharmacology, Volume 12, Number 1, 2017, pp. 31-35(5)

  1. Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot

The effectiveness of

 finasteride and dutasteride used for 3 years in women with androgenetic alopecia. Indian J Dermatol Venereol Leprol 2014;80:521-525

  1. Fertig, R. M, Gamret, A. C, Darwin, , & Gaudi, S. (2017).

Sexual side effects of 5-α-reductase inhibitors finasteride and dutasteride: A comprehensive review. Dermatology Online Journal, 23(11).

  1. Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian J Dermatol Venereol Leprol. 2017 Jan-Feb;83(1):47-54. doi: 10.4103/0378-6323.188652. PMID: 27549867.
  1. Gupta AK, Charrette A. The efficacy and safety of 5α-reductase inhibitors in androgenetic alopecia: a network meta-analysis and benefit-risk assessment of finasteride and dutasteride. J Dermatology Treat. 2014 Apr;25(2):156-61. doi: 10.3109/09546634.2013.813011. Epub 2013 Jul 5. PMID: 23768246.
  1. Sergio Vañó-Galván, David Saceda-Corralo, Oscar M. Moreno-Arrones, Rita Rodrigues-Barata, Carlos Morales, Rocío Gil-Redondo, Claudia Bernárdez-Guerraet al 

Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: A descriptive monocentric study

Dermatologic Therapy Therapeutic Hotline: Letter First published: 10 December 2019 https://doi.org/10.1111/dth.13182

  1. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research Team. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006 Dec;55(6):1014-23. doi: 10.1016/j.jaad.2006.05.007. PMID: 17110217.
  2. Nestor MS, Ablon G, Gade A, Han H, Fischer DL. Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics. J Cosmet Dermatol. 2021 Dec;20(12):3759-3781. doi: 10.1111/jocd.14537. Epub 2021 Nov 6. PMID: 34741573; PMCID: PMC9298335.
  1. Eun, Hee Chul et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: A randomized, double-blind, placebo-controlled, phase III study Journal of the American Academy of Dermatology, Volume 63, Issue 2, 252 – 258

 

  1. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, Walker SE, Haberer LJ, Clark RV. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab. 2007 May;92(5):1659-65. doi: 10.1210/jc.2006-2203. Epub 2007 Feb 13. Erratum in: J Clin Endocrinol Metab. 2007 Nov;92(11):4379. PMID: 17299062.

Footnotes:

1. Board Certified Dermatologist: A Board-Certified Dermatologist is a physician that has graduated from Medical School, completed at least a 4-year postgraduate residency training program in Dermatology, demonstrated clinical competence in the care of patients, met the procedural and licensure requirements, taken and passed the American Board of Dermatology Certification Examination. Certification by the American Board of Dermatology affirms that a Dermatologist has met high standards set by their peers and has extensive knowledge, experience and training which allows them to accurately diagnose and properly treat more than 3,000 diseases of the skin, hair, and nails. https://www.abderm.org

2. Androgens are hormones that are chemical messengers in the body. In the case of our products, they transmit information to a protein androgen receptor located in the root of the hair follicle that has an important function in both males and females, such as regulating hair growth and sex drive. The most well-known androgen is probably testosterone. Dihydrotestosterone (DHT) is a sex hormone that is a derivative of testosterone and is thought to attach to a protein androgen receptor in the hair follicle root. Excess amounts of the DHT hormone can affect the hair’s growth cycle, shrinking and shortening the hair, making it easier for it to fall out and more difficult for it to grow back.

3. Crown of scalp: The crown is the highest point on your scalp, toward the back of your head.

4. FDA insert: Side effects of Finasteride: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/020788Orig1s020.pdf

5. FDA insert: Side effects of Dutasteride https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021319s015lbl.pdf

6. FDA insert: Side effects of Minoxidil https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018154s026lbl.pdf

7. FDA insert: Side effects of Spironolactone https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/012151s075lbl.pdf